The genetic basis of the endocannabinoid system and drug addiction in humans

Journal of Psychopharmacology - Tập 26 Số 1 - Trang 133-143 - 2012
José Antonio López‐Moreno1, Víctor Echeverry‐Alzate1, Kora‐Mareen Bühler1
1Department of Psychobiology, Faculty of Psychology, Complutense University, Madrid, Spain

Tóm tắt

The cannabinoid receptor ( CNR1) and the fatty acid amide hydrolase ( FAAH) genes are located on chromosomes 6 and 1 in the 6q15 and 1p33 cytogenetic bands, respectively. CNR1 encodes a seven-transmembrane domain protein of 472 amino acids, whereas FAAH encodes one transmembrane domain of 579 amino acids. Several mutations found in these genes lead to altered mRNA stability and transcription rate or a reduction of the activity of the encoded protein. Increasing evidence shows that these functional mutations are related to dependence upon cocaine, alcohol, marijuana, heroin, nicotine and other drugs. One of the most compelling associations is with the C385A single nucleotide polymorphism (SNP), which is found in the FAAH gene. For all of the genetic polymorphisms reviewed here, it is difficult to form overall conclusions due to the high diversity of population samples being studied, ethnicity, the use of volunteers, heterogeneity of the recruitment criteria and the drug addiction phenotype studied. Care should be taken when generalizing the results from different studies. However, many works have repeatedly associated polymorphisms in the CNR1 and FAAH genes with drug-related behaviours; this suggests that these genes should be examined in further genetic studies focusing on drug addiction and other psychiatric disorders.

Từ khóa


Tài liệu tham khảo

10.1002/ajmg.b.30881

10.1016/S0301-0082(98)00087-2

10.1016/j.pbb.2005.02.015

10.1038/sj.tpj.6500352

10.1038/sj.tpj.6500301

10.2174/092986607780090829

10.1146/annurev.clinpsy.032408.153545

10.1111/j.1369-1600.2009.00198.x

10.1016/j.bcp.2010.02.013

10.1001/archpsyc.65.7.816

10.1093/hmg/ddh216

10.1097/00008877-200209000-00018

10.1016/j.ejphar.2004.07.069

10.1016/j.pbb.2005.01.022

10.1038/sj.mp.4000247

10.1038/sj.mp.4000925

10.1016/j.lfs.2005.05.055

10.1038/npp.2009.166

10.1111/j.1755-5949.2010.00144.x

10.1038/npp.2009.200

10.1007/s00439-006-0250-x

10.1007/s00213-009-1569-5

10.1016/S0741-8329(03)00098-3

10.1016/j.pbb.2005.01.032

10.1038/sj.npp.1301648

10.1016/j.biopsych.2008.10.047

10.1016/j.drugalcdep.2009.01.022

10.1111/j.1360-0443.2008.02292.x

10.1080/13556210020040271

10.1073/pnas.87.5.1932

10.1002/ajmg.b.30378

10.1001/archpsyc.65.7.841

10.1016/S0306-4522(03)00070-8

10.1074/jbc.M109.058461

10.1126/science.278.5335.52

Krebs Mo, 2003, Schizophr Res, 53, 72

10.1385/NMM:5:1:085

10.1038/sj.mp.4000670

10.2174/138945010790980312

10.1007/3-540-26573-2_10

10.2174/138945010790980358

10.1016/j.tins.2006.01.008

10.1007/s00406-006-0665-3

10.1038/346561a0

10.1523/JNEUROSCI.3221-08.2008

10.1016/j.phrs.2010.01.002

10.1016/j.neuropharm.2007.07.005

10.1016/j.neulet.2004.11.050

10.1038/81570

10.1016/S0301-0082(02)00007-2

Pertwee RG, 2006, J Pharmacol, 147, 163

10.1038/nrn1247

10.1016/j.neuropharm.2004.07.018

10.1038/tpj.2009.59

10.1093/alcalc/agh110

10.1016/j.febslet.2004.11.085

10.1007/s00213-008-1397-z

10.2174/187152708786927859

10.1016/S0376-8716(01)00164-8

10.1016/S0021-9258(19)49776-7

10.1073/pnas.082235799

10.1038/bjp.2008.130

10.1016/S0306-4522(99)00086-X

10.1002/ajmg.b.30491

10.1111/j.1369-1600.2007.00064.x

10.1007/s00213-006-0506-0

10.1074/jbc.M606646200

10.1124/mol.109.055251

10.1016/j.biopsych.2006.12.004

10.1038/npp.2008.206

Thông tin
Thông tin xuất bản

Journal of Psychopharmacology

Tập 26 Số 1

133-143

Thông tin tác giả